WEE1 Inhibitor: Clinical Development

被引：0
|
作者：
Anthony Kong
Hisham Mehanna
机构：
[1] University of Birmingham,Institute of Head and Neck Studies (InHANSE)
[2] King’s College London,Comprehensive Cancer Centre
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
WEE1 inhibitor; Adavosertib; AZD1775; TP53 mutation; Biomarker; Clinical trials;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Temporal phosphoproteomics reveals WEE1-dependent control of 53BP1 pathway
    Petrosius, Valdemaras
    Benada, Jan
    Nielsen, Olaf
    Schoof, Erwin M.
    Sorensen, Claus Storgaard
    ISCIENCE, 2023, 26 (01)
  • [42] Clinical development of IDH1 inhibitors for cancer therapy
    Zarei, Mehrdad
    Hue, Jonathan J.
    Hajihassani, Omid
    Graor, Hallie J.
    Katayama, Erryk S.
    Loftus, Alexander W.
    Bajor, David
    Rothermel, Luke D.
    Vaziri-Gohar, Ali
    Winter, Jordan M.
    CANCER TREATMENT REVIEWS, 2022, 103
  • [43] LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma
    Xuqiang Zhu
    Di Chen
    Yiyu Sun
    Shuo Yang
    Weiguang Wang
    Bing Liu
    Peng Gao
    Xueyuan Li
    Lixin Wu
    Siqi Ma
    Wenyang Lin
    Jiwei Ma
    Dongming Yan
    BMC Cancer, 23
  • [44] LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma
    Zhu, Xuqiang
    Chen, Di
    Sun, Yiyu
    Yang, Shuo
    Wang, Weiguang
    Liu, Bing
    Gao, Peng
    Li, Xueyuan
    Wu, Lixin
    Ma, Siqi
    Lin, Wenyang
    Ma, Jiwei
    Yan, Dongming
    BMC CANCER, 2023, 23 (01)
  • [45] The function and clinical implication of YTHDF1 in the human system development and cancer
    Wenjun Ren
    Yixiao Yuan
    Yongwu Li
    Luciano Mutti
    Jun Peng
    Xiulin Jiang
    Biomarker Research, 11
  • [46] The function and clinical implication of YTHDF1 in the human system development and cancer
    Ren, Wenjun
    Yuan, Yixiao
    Li, Yongwu
    Mutti, Luciano
    Peng, Jun
    Jiang, Xiulin
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [47] Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
    Dhani, Neesha
    Siu, Lillian L.
    CANCER AND METASTASIS REVIEWS, 2008, 27 (03) : 339 - 349
  • [48] Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
    Neesha Dhani
    Lillian L. Siu
    Cancer and Metastasis Reviews, 2008, 27 : 339 - 349
  • [49] Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase - 1st communication: The contribution of clinical pharmacology
    Kuhlmann, J
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2004, 54 (05): : 251 - 258
  • [50] A NIR fluorescent probe for Vanin-1 and its applications in imaging, kidney injury diagnosis, and the development of inhibitor
    Tian, Zhenhao
    Yan, Fei
    Tian, Xiangge
    Feng, Lei
    Cui, Jingnan
    Deng, Sa
    Zhang, Baojing
    Xie, Tian
    Huang, Shanshan
    Ma, Xiaochi
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (01) : 316 - 325
12345